Nargiza Parpieva

49 та иш

Tashkent Medical Academy , Tashkent, Uzbekistan

Detection of Nontuberculosis Mycobacteria in National Reference Laboratory (NRL) of Uzbekistan
Sanjar Sultanov, Nargiza Parpieva, Kazim Mukhamedov +3
МақолаMycobacterium research and diagnosisTuberculosis20200 иқтибос
ABI
Adverse Drug Reactions among Children with Tuberculosis in Tashkent, Uzbekistan, 2019
Makhliyo Abdusalomova, Olga Denisiuk, Hayk Davtyan +4
МақолаTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017–2018
Zayniddin Sayfutdinov, Ajay Kumar, Dilyara Nabirova +5
МақолаTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
Incidence Rate and Risk Factors for Tuberculosis among People Living with HIV: A 2015–2017 Cohort from Tashkent, Uzbekistan
Dilbar Sadirova, Ruzanna Grigoryan, Nargiza Parpieva +9
МақолаPneumocystis jirovecii pneumonia detection and treatmentInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
Characteristics and Treatment Outcomes of Patients with Tuberculosis Receiving Adjunctive Surgery in Uzbekistan
Anvar Riskiyev, Ana Ciobanu, Arax Hovhannesyan +3
МақолаDiagnosis and treatment of tuberculosisInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
Universal Access to Xpert MTB/RIF Testing for Diagnosis of Tuberculosis in Uzbekistan: How Well Are We Doing?
Laziz Turaev, Ajay Kumar, Dilyara Nabirova +3
МақолаTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
Adherence of drug-resistant tuberculosis patients to treatment in Tashkent, 2019-2020
Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +3
МақолаTuberculosis Research and Epidemiology20210 иқтибос
ABI
Hospitalizations and Treatment Outcomes in Patients with Urogenital Tuberculosis in Tashkent, Uzbekistan, 2016–2018
Bakhtiyor Ismatov, Yuliia Sereda, S Sahakyan +2
МақолаTuberculosis Research and EpidemiologyInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
Accuracy of molecular drug susceptibility testing amongst tuberculosis patients in Karakalpakstan, Uzbekistan
Horacio Gil, Hasmik Margaryan, I. Azamat +8
МақолаTuberculosis Research and EpidemiologyTropical Medicine & International Health20210 иқтибос
ABI
Non-tuberculous mycobacteria in phthisiopulmonary practice in the Republic of Uzbekistan
Nargiza Parpieva, S Sultanov, M. Kh. Dzhurabaeva +1
МақолаMycobacterium research and diagnosisTuberculosis and lung diseases20210 иқтибос
ABI
Treatment of multidrug-resistant tuberculosis in Uzbekistan from 2012 to 2018: does practice follow policy?
Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +8
МақолаTuberculosis Research and Epidemiology20210 иқтибос
ABI
Is Xpert MTB/Rif Ultra superior to Xpert MTB/Rif for the diagnosis of tuberculosis in children in Uzbekistan
Sanjar Sultanov, Nargiza Parpieva, Kozim Mukhamedov +3
МақолаIdeological and Political Education20210 иқтибос
ABI
Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
Jamshid Gadoev, Anthony Harries, Oleksandr Korotych +7
Таҳририят мақоласиDiverse Scientific Research StudiesInternational Journal of Environmental Research and Public Health20210 иқтибос
ABI
The impact of the COVID-19 pandemic on tuberculosis detection in Tashkent, Uzbekistan
Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +6
МақолаDiverse Scientific Research Studies20230 иқтибос
ABI
Introducing BPaL: Experiences from countries supported under the LIFT-TB project
D. F. Wares, M. Mbenga, Veriko Mirtskhulava +19
МақолаTuberculosis Research and EpidemiologyPLoS ONE20240 иқтибос
ABI
How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial
Ilaria Motta, Martina Cusinato, Andrew Ludman +15
МақолаCardiac electrophysiology and arrhythmiasAntimicrobial Agents and Chemotherapy20240 иқтибос
ABI
Second-line drug-resistant TB and associated risk factors in Karakalpakstan, Uzbekistan
S. Moe, I. Azamat, Sholpan Allamuratova +14
МақолаTuberculosis Research and EpidemiologyIJTLD OPEN20240 иқтибос
ABI
Study the Occurrence of Mycobacterium Bovis in Tuberculosis of Peripheral Lymph Nodes and its Effect on the Course of the Disease.
Nargiza Parpieva, Askar Anvarovich Adilkhodzhaev, Zarifa Abdiraubovna Muminova
МақолаTuberculosis Research and EpidemiologyBiomedical & Pharmacology Journal20240 иқтибос
ABI
Features of colposcopy in patients with various forms of pulmonary tuberculosis
Marufdjon Yuldashev, Nargiza Parpieva, Shaxnoza Zufarova
МақолаDiagnosis and treatment of tuberculosis20240 иқтибос
ABI
The effectiveness of pulmonary tuberculosis treatment during the COVID-19 pandemic
Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko +6
МақолаCOVID-19 Prevention and Impact20240 иқтибос
ABI
A 10-year review of isoniazid-resistant TB management in Uzbekistan 2009-2020
Michael L. Rekart, Phone Thit, Modupe Oluya +14
Шарҳ мақолаTuberculosis Research and EpidemiologyIJTLD OPEN20240 иқтибос
ABI
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan
Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22
МақолаTuberculosis Research and EpidemiologyClinical Infectious Diseases20250 иқтибос
ABI
Evaluation of TB treatment outcomes in outpatient settings during the COVID-19 pandemic
Ruzilya Usmanova, Nargiza Parpieva, Irina Liverko
МақолаTuberculosis Research and Epidemiology20250 иқтибос
ABI
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis
Anthony J. Garcia‐Prats, Maria Garcia‐Cremades, Vivian Cox +97
Шарҳ мақолаTuberculosis Research and EpidemiologyThe Lancet Child & Adolescent Health20250 иқтибос
ABI